The anti-myeloma activity of bone morphogenetic protein 2 predominantly relies on the induction of growth arrest and is apoptosis-independent-Reference-Cited by-同舟云学术

The anti-myeloma activity of bone morphogenetic protein 2 predominantly relies on the induction of growth arrest and is apoptosis-independent

Published:2017-10-13 Issue:10 Volume:12 Page:e0185720
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Lagler Charlotte,El-Mesery Mohamed,Kübler Alexander Christian,Müller-Richter Urs Dietmar Achim,Stühmer Thorsten,Nickel Joachim,Müller Thomas Dieter,Wajant Harald,Seher Axel^ORCID

Funder

Deutsche Forschungsgemeinschaft

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference49 articles.

1. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management;SV Rajkumar;American journal of hematology,2011

2. Therapeutic approaches to myeloma bone disease: an evolving story;V Longo;Cancer treatment reviews,2012

3. Autologous hematopoietic stem-cell transplantation for multiple myeloma;JL Harousseau;The New England journal of medicine,2009

4. Chromosome translocations in multiple myeloma;PL Bergsagel;Oncogene,2001

5. Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma;A Anguiano;Journal of clinical oncology: official journal of the American Society of Clinical Oncology,2009

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CXCR4 expression of multiple myeloma as a dynamic process: influence of therapeutic agents;Leukemia & Lymphoma;2022-07-08

2. Targeting inhibitors of apoptosis in oral squamous cell carcinoma in vitro;Journal of Cranio-Maxillofacial Surgery;2019-10

3. The Selection of NFκB Inhibitors to Block Inflammation and Induce Sensitisation to FasL-Induced Apoptosis in HNSCC Cell Lines Is Critical for Their Use as a Prospective Cancer Therapy;International Journal of Molecular Sciences;2019-03-15

4. LncRNA PRAL is closely related to clinical prognosis of multiple myeloma and the bortezomib sensitivity;Experimental Cell Research;2018-09

5. In vitro assays and techniques utilized in anticancer drug discovery;Journal of Applied Toxicology;2018-08-02